Collaboration

Partnering With Us

At Asahi Kasei Therapeutics, we are embracing transformation for future growth through both internal innovation and strategic collaborations. As a well-capitalized, global specialty pharmaceutical business, we are actively expanding our portfolio of solutions to address significant unmet medical needs.

Global Focus Areas

We seek new business development opportunities such as in-license, research collaboration, investment and M&A in these disease areas:

  • Transplant
  • Nephrology
  • Immunology
  • Infectious Diseases

Why Partner With Asahi Kasei Therapeutics?

  • Development Capability: Asahi Kasei Therapeutics brings extensive experience in advancing therapeutic candidates through all stages of development. Our approach integrates global R&D resources, including the Pharmaceuticals Research Center, which combines in-house research and open innovation activities across target therapeutic areas.
  • Commercial Capability: We have a proven track record in the successful commercialization of therapies. Our U.S.-based commercial teams are supported by strong international partners and a growing presence in Europe, enabling rapid market access and operational readiness at launch.
  • Regulatory Affairs Expertise: Our regulatory affairs team has demonstrated experience in engaging with global health authorities, including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and Pharmaceuticals and Medical Devices Agency (PMDA). These collaborative relationships support our ability to navigate complex regulatory pathways effectively.
  • Support from Asahi Kasei Group: As a strategic priority within Asahi Kasei Group, we actively benefit from proactive resource allocation to drive long-term growth and continued investment, strengthening our ability to identify and develop new therapeutic options.

Ways to Collaborate

We take a collaborative, cross-functional approach to identifying and prioritizing high-potential therapeutic areas, including transplantation, nephrology, immunology and infectious diseases. We welcome partners who share our commitment to bold science and making a meaningful impact in areas where new treatments are not just wanted but urgently needed.

Our business development activities take many forms:

  • Licensing and M&A with peer companies, biotechs and academia to enhance our pipeline across our therapeutic areas. We are focused on in-licensing late-stage assets and are actively evaluating strategic M&A opportunities. We are open to considering out-licensing certain pipeline agents.
  • Open Innovation: We actively promote open innovation and seek in-licensing of early-stage assets and research collaboration opportunities in drug discovery. To learn more about our Open Innovation activities, click here.
  • Corporate Venture Capital (CVC): Asahi Kasei Ventures is a strategic CVC arm that directly invests in early-stage biotech companies, primarily aligned with our therapeutic focus areas, but with flexibility beyond them. To learn more about CVC click here.

Contact Us

Reach out to our Business Development Team for more information:

busdev@aktx.com

US-AKTX-2600009 V1.0 6/26